Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a computer game fix 'Spatial Neglect' after stroke?

NCT ID NCT07519317

Symptom relief Sponsor: Duke University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a home-based eye movement therapy (optokinetic stimulation) for people with spatial neglect after a stroke. Spatial neglect makes it hard to pay attention to one side of the world, often leading to falls. The therapy involves watching moving dots on a computer screen to train the eyes to scan the neglected side. The trial will enroll 90 adults over 60 who had a stroke more than 6 months ago, and will measure improvements in mobility and daily function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
optokinetic stimulation (visual scanning therapy on a computer)
What this could lead to
If it works, this could provide an effective home-based treatment for spatial neglect after stroke, improving mobility and reducing fall risk.
What could go wrong
This is an early-stage trial with only 90 participants, and previous evidence for such treatments is mixed. The therapy may not work for everyone or may be difficult to use at home.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 110 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for stroke group: 1. first and unilateral right brain damage stroke, confirmed by medical records, 2. time post stroke \>6 months, 3. moderate to severe SN, classified using the Catherine Bergego Scale (CBS) via the Kessler Foundation Neglect Assessment Process (KF-NAP), 4. over age of 60 years, and 5. IGD noted either on the KF-NAP or neuroimaging from medical records. Exclusion Criteria for stroke group: 1. history of multiple strokes or neurological incidents (e.g., traumatic brain injury, seizures, or brain tumor), 2. unable to communicate through spoken English, screened using the Aphasia Rapid Test (ART), as instructions for treatment and assessment tasks will be provided verbally in English, 3. cognitive impairment as defined by the Blind-MoCA, 4. dependent in mobility- walking or wheelchair via medial chart, 5. legally blind per medical chart, 6. home located out of a 50-mile radius from Duke University, making it too costly for the frequent home visits, and 7. no IGD present. Inclusion Criteria for caregiver group: 1. a current care partner (defined as someone providing care and assistance) of a stroke survivor living with SN, 2. English speaker, 3. the stroke survivor they are caring for has been enrolled into the study. Exclusion Criteria for caregiver group: 1. not a care partner currently, 2. can't speak English, 3. the stroke survivor didn't consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spatial neglect are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

perceptual disorders stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spatial neglect

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.